Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug aims to stop EBV in kidney transplants

NCT ID NCT07368153

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 26, 2026 · Updated 4 times

Summary

This study tests whether an IDO-1 inhibitor can safely prevent Epstein-Barr virus (EBV) infection in kidney transplant recipients who have never had EBV but receive a kidney from an EBV-positive donor. Nine participants will receive either the drug or a placebo for 28 days, alongside standard care, and be monitored for side effects and viral changes. The goal is to see if the drug is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IDO-1 inhibitor
What this could lead to
If it works, this could help prevent serious EBV-related complications in kidney transplant patients who are at risk.
What could go wrong
This is a very small early-phase trial with only 9 participants, so results may not apply broadly. The drug may cause side effects or fail to prevent EBV infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 9 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing and able to provide informed consent 2. Male or female aged ≥18 years 3. EBV seronegative at the time of renal transplant 4. If women of child-bearing potential (WOCBP), participants must have a negative serum pregnancy test at screening and inclusion, and must be willing to use a highly effective method of birth control for the duration of the study. Acceptable methods of contraception: 1. Hormonal contraception associated with inhibition of ovulation 2. Intrauterine device (IUD) 3. Intrauterine hormone-releasing system (IUS) 4. Bilateral tubal occlusion 5. Vasectomised partner 6. Condom with spermicide 7. Sexual abstinence, in line with the preferred and usual lifestyle of the participant. Periodic abstinence (such as calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 5. If male, participants must be prepared to use reliable barrier method contraception and a second method such as spermicide for the duration of the study unless surgically sterile. Exclusion Criteria: 1. EBV seropositivity at the time of transplant 2. Participants with any form of cancer within the last 12 months, or patients continuing to receive chemo or immunotherapy within the last 12 months. 3. Participants with a history of PTLD 4. Other active systemic infections requiring treatment prior to and at the time of baseline. Prophylactic agents are permitted. 5. CYP3A4 and CYP2C28 Inhibitors and Inducers (List may be found in Appendix 1) 6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3 x ULN 7. Any condition for which, in the opinion of the investigator, the treatment or participation in the study may pose a health risk to the participant 8. Planned or active participation in any other study with an investigational medicinal product (IMP). 9. Have taken an IMP within the last 3 months. 10. Unwilling or unable to provide fully informed consent. 11. Unwilling or unable to comply with study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre hospitalier universitaire vaudois (CHUV)

    NOT_YET_RECRUITING

    Lausanne, Lausanne, 1011, Switzerland

  • University Hospital Basel

    NOT_YET_RECRUITING

    Basel, 4031, Switzerland

  • University Hospital Bern

    RECRUITING

    Bern, Canton of Bern, 3010, Switzerland

  • University Hospital Zurich

    NOT_YET_RECRUITING

    Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.